AI could revolutionise pharma compound synthesis
pharmaphorum
JANUARY 15, 2024
Researchers at the University of Cambridge and Pfizer have developed an AI-powered approach to make it easier to design and make pharma molecules
Sat.Jan 13, 2024 - Fri.Jan 19, 2024
115 
Former Pfizer statistician found guilty of insider trading on Paxlovid trial results
Fierce Pharma
JANUARY 19, 2024
A jury has found a former Pfizer statistician guilty of insider trading after a two-week trial in federal court in the Southern District of New York. | A federal jury has found a former Pfizer statistician guilty of insider trading after a two-week trial in Manhattan. The jury convicted Amit Dagar, 44, of Hillsborough, N.J., of using advance information on successful trial results for Pfizer’s COVID-19 treatment Paxlovid to make more than $270,000 in stock trades.
Join 8,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Ex-Pfizer Employee Convicted for Insider Trades Ahead of Positive Paxlovid Data
MedCity News
JANUARY 19, 2024
The former Pfizer statistician worked on the clinical trial for the Covid-19 drug Paxlovid. A jury found the employee guilty of insider trading for transactions made before clinical data for the antiviral were publicly announced.
Three ways research offices can lead researchers to more funding
Clarivate
JANUARY 19, 2024
Over half of research office leaders say researchers are disengaged. How can you close the gap to win more funding? In late 2023, Research Professional News, an editorially independent part of Clarivate , surveyed research office leaders and staff as well as researchers around the world, taking a close look at the challenges facing them today and in the future.
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
UK ATMP sector “robust”, research finds
European Pharmaceutical Review
JANUARY 18, 2024
An attractive destination for ATMP clinical trials Based on the Cell and Gene Therapy Catapult (CGT Catapult)’s recently published UK 2023 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database , the UK is an attractive location for ATMP clinical trials. This is largely due to the number of ongoing ATMP clinical trials in the UK remaining “largely stable” over the past three years.
After row with Hungary and Poland, Pfizer sues Romania over missed COVID vaccine payments
Fierce Pharma
JANUARY 19, 2024
Following public spats with Hungary and Poland, Pfizer and its German mRNA partner BioNTech have kicked off legal proceedings against Romania. | Following public spats with Hungary and Poland, Pfizer and its German mRNA partner BioNTech have kicked off legal proceedings against Romania. The lawsuit marks the latest move in Pfizer’s campaign to press countries to honor COVID-19 vaccine contracts inked by the European Commission in May 2021.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
Women’s health gap estimated at $1trn in new report
pharmaphorum
JANUARY 17, 2024
The disparity in access to healthcare between women and men around the world is often talked about but has never been given a dollar value – until now.
Keytruda Granted Latest FDA Approval in Cervical Cancer
Pharmaceutical Commerce
JANUARY 15, 2024
FDA approves Keytruda (pembrolizumab) combined with chemoradiation for the treatment of patients with FIGO 2014 stage III to IVA cervical cancer, which is the 39th overall approved indication for the drug in the United States.
Bayer CEO Bill Anderson makes his mark with major restructuring, 'significant' job cuts
Fierce Pharma
JANUARY 17, 2024
Bayer is launching a sweeping business overhaul as the German conglomerate sees “no viable alternative.” | Bayer is launching a sweeping business overhaul that will “come at the expense of many managerial employees,” as the German conglomerate sees “no viable alternative.
9 Hot Takes from JPM24
MedCity News
JANUARY 15, 2024
I didn’t make it to this year’s J.P. Morgan Healthcare Conference in San Francisco, so I reached out to leaders from across the industry to hear how it went and learn about their takeaways from the event. This is a list of the nine most interesting responses that I received.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
New anti-smoking drug set for rapid NHS rollout
pharmaphorum
JANUARY 17, 2024
Oral cytisine therapy for smoking cessation from Consilient Health will launch in the UK next week, helping to alleviate a shortage of prescription drugs to help people quit
MHRA approves ‘safer’ medicine alternative for rare disease
European Pharmaceutical Review
JANUARY 15, 2024
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree ® (vamorolone), as a safer alternative to corticosteroids, for Duchenne muscular dystrophy (DMD). “In addition to its anti-inflammatory efficacy, both the EMA and the MHRA recognise the benefits of treatment with Agamree for bone health and growth,” Dr Shabir Hasham, Chief Medical Officer of Santhera Pharmaceuticals shared.
Bristol Myers shows power of Opdivo-Yervoy combo in first-line colorectal cancer subset
Fierce Pharma
JANUARY 19, 2024
More than five years after an FDA accelerated approval in a subtype of progressive colorectal cancer, Bristol Myers Squibb now has data supporting its checkpoint inhibitor doublet in newly diagnose | More than five years after an FDA accelerated approval in a subtype of progressive colorectal cancer, Bristol Myers Squibb now has data supporting its checkpoint inhibitor doublet in newly diagnosed patients.
Deloitte: 7 Trends Shaping Healthcare and Life Sciences in 2024
MedCity News
JANUARY 19, 2024
AI, health equity and merger and acquisition activity are among the trends to watch in 2024, according to a recent report from Deloitte.
The Impact of Eli Lilly's New DTC Platform on Rx Drug Sales and Patient Access: An Interview with Bill Roth, General Manager, Managing Partner, Blue Fin Group
Pharmaceutical Commerce
JANUARY 18, 2024
In an interview with Pharma Commerce editor Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.
NICE backs Pfizer’s Talzenna for advanced breast cancer
pharmaphorum
JANUARY 18, 2024
Pfizer’s PARP inhibitor Talzenna has become the first targeted treatment for HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations to be recommended by NICE for routine NHS use.
Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia
Fierce Pharma
JANUARY 16, 2024
Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FD | Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval came more than two months ahead of the FDA's March 30 decision date.
Boulder Care Extends Virtual Substance Use Disorder Treatment to Adolescents
MedCity News
JANUARY 16, 2024
As the opioid crisis grows for teens, Boulder Care has expanded its substance use disorder treatment to support adolescents. The company is starting its adolescent services in Washington with UnitedHealthcare Community Plan.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Could novel antibiotic successfully treat a ‘priority 1 pathogen’?
European Pharmaceutical Review
JANUARY 19, 2024
According to GlobalData, with demonstrated efficacy against carbapenem-resistant Acinetobacter Baumanni (CRAB), Roche’s zosurabalpin “has the potential to treat lethal hospital infection,” Anaelle Tannen, Infectious Disease Analyst at GlobalData explained. Currently in Phase I development , the antibiotic’s novel mechanism of action was showcased through its effectiveness against the pathogen in in vitro studies.
Roche bags EU okay for subcutaneous Tecentriq
pharmaphorum
JANUARY 16, 2024
Roche’s Tecentriq has become the first PD-1/PD-L1 inhibitor to be cleared in the EU in a subcutaneous form that will make dosing easier for patients and healthcare providers
AstraZeneca adds to rare blood disease portfolio with world-first Voydeya approval in Japan
Fierce Pharma
JANUARY 19, 2024
A month after Novartis made its entry into the paroxysmal nocturnal haemoglobinuria (PNH) field, AstraZeneca’s newest contender Voydeya bolsters the company’s presence in the disease area with a wo | The drug bolsters the company's portfolio in paroxysmal nocturnal haemoglobinuria (PNH) just as the market heats up thanks to new competitors from Novartis and Apellis.
More Than a Survey: How to Holistically Embrace the Patient Experience
MedCity News
JANUARY 16, 2024
Despite the challenges that healthcare providers face and declining patient experience scores, several effective strategies can enhance their work to improve the patient experience and sufficiently satisfy expectations for care.
How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Market outlook to 2032: future trends across the seven major markets
European Pharmaceutical Review
JANUARY 18, 2024
The treatment markets for two key diseases areas: insomnia and the rare metabolic disorder, Gaucher disease, are predicted to flourish in the seven major markets (7MM – France, Germany, Italy, Spain, UK, US, and Israel) in 2032, data and analytics company GlobalData suggests. Insomnia market Dual orexin receptor antagonists (DORAs) [dual orexin receptor antagonists (DORAs)]… offer a new mechanism of action [in treating insomnia]” Across the seven major markets, the insomnia mar
AZ bags first approval for PNH therapy danicopan, in Japan
pharmaphorum
JANUARY 19, 2024
AstraZeneca gets its first approval for oral Factor D inhibitor danicopan, in Japan, for treatment of paroxysmal nocturnal haemoglobinuria
GSK pumps £200M+ into UK manufacturing network to bolster commercial ambitions, API supply
Fierce Pharma
JANUARY 16, 2024
As British pharma giant AstraZeneca looks abroad to build new factories, GSK is sticking close to home, where it plans to plug hundreds of millions of pounds into the United Kingdom over the next t | As other British drugmakers like AstraZeneca look abroad to build new factories, GSK is sticking close to home, where it plans to plug hundreds of millions of pounds into the United Kingdom over the next two years.
CMS Finalizes Rule Streamlining Prior Authorization Process
MedCity News
JANUARY 17, 2024
CMS finalized a rule on Wednesday that included set deadlines for affected payers to complete prior authorization requests. Several organizations came out in support of the rule.
How to Stay Competitive in the Evolving State of Martech
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
NICE recommends innovative breast cancer drug
European Pharmaceutical Review
JANUARY 19, 2024
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Pfizer’s TALZENNA ® (talazoparib) for HER2- negative, locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations. An important advance in treating breast cancer The pharmaceutical company shared that its oral small molecule poly (ADP-ribose) polymerase (PARP) inhibitor is indicated in adults who have had an anthracycline or a taxane, or both, if suitable,
FDA clears AI skin cancer detection device from DermaSensor
pharmaphorum
JANUARY 18, 2024
Medtech company DermaSensor gets FDA approval for a handheld device, powered by AI, that can be used to detect skin cancer at the point of care
After Pfizer offers discount, NICE gives thumbs up to breast cancer drug Talzenna
Fierce Pharma
JANUARY 18, 2024
Six months after England’s National Institute for Health and Care Excellence (NICE) spurned Pfizer’s breast cancer treatment Talzenna (talazoparib) because it was not cost effective, the agency has | Six months after England’s National Institute for Health and Care Excellence spurned Pfizer’s breast cancer treatment Talzenna because it was not cost effective, the agency has reversed course following the company’s offer to slash the price.
AMA President: Medicare Physician Pay Cuts Will Have ‘Dire’ Impact if Not Reversed
MedCity News
JANUARY 17, 2024
The Medicare physician pay cuts that went into effect January 1 is a “disaster for the profession,” said Dr. Jesse Ehrenfeld, president of the AMA, during an interview at CES 2024. Getting the pay cut reversed is a top priority for the organization.
Let's personalize your content